Hansa Biopharma AB (SE:HNSA)
:HNSA
Want to see SE:HNSA full AI Analyst Report?
Earnings Data
Report Date
Jul 16, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-1.66Last Year’s EPS
-2.53Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Q1 2026
Earnings Call Date:Apr 23, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
Balanced call: significant positive developments on financing, regulatory progress (BLA review, PAES lock, ConfIdeS presentation), promising next-generation asset data (5487), and concrete market-access wins (Catalonia, German KOL guidance) are offset by a steep revenue decline (‑48% Y/Y), ongoing high cash burn and operating losses, and continued structural volatility in European organ allocation. Management emphasizes stabilization actions completed and expects benefits to materialize over coming months, but short-term revenue predictability remains limited.Company Guidance
Raised $30M Convertible Note Extending Runway
Entered a USD 30 million convertible note purchase agreement (fixed 3% interest, semiannual cash payments from Sep 15, 2026, maturity Mar 2031) on Mar 19, 2026, strengthening the balance sheet ahead of potential U.S. approval and launch.
Cash Position and Debt Reduction
Cash and cash equivalents totaled SEK 677 million at quarter end; paid down NovaQuest debt by ~SEK 15 million in January and have no additional payment due until mid-2027.
Regulatory and Clinical Milestones Progressing
BLA review with FDA initiated and described as progressing 'as expected' with no unusual questions; PAES database lock expected next month; ConfIdeS Phase III data accepted for oral presentation at ATC in June; plan to file for full EMA approval in Q4 and PDUFA in December.
Promising Next-Generation Program (5487) and GBS Development
First-in-human study of HNSA-5487 completed: >95% reduction in circulating IgG within hours, clear dose–response for duration, lower anti-drug antibody response vs imlifidase, safe and well tolerated; briefing submitted to FDA for GBS program with clinical phase planned to start by year-end pending FDA feedback expected in May.
Commercial Preparations for U.S. Launch
Full commercial build planned in Q4; focused U.S. site strategy on top 100 centers (approx. 80% transplant volume) with 25 ConfIdeS centers representing ~25% of volume; market-access planning ongoing (NTAP and Outlier payment strategies) and distribution/supply-chain arrangements in progress.
European Market Access Wins and Operational Improvements
Secured regional reimbursement in Catalonia effective Apr 1 (first sale post-Q1); German KOL consensus recommendations rolled out and submitted for publication (expected mid-2026); implemented new commercial systems (CRM, dashboards) and pan-European physician education to improve transparency and performance.
Cost Control in R&D
R&D expense in Q1 2026 totaled ~SEK 57 million, reported as 11% (SEK 7 million) favorable versus Q1 2024 (attributed to wind-down of certain clinical activities and 2025 restructuring).
SE:HNSA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SE:HNSA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 23, 2026 | kr27.12 | kr24.88 | -8.26% |
Feb 11, 2026 | kr36.98 | kr38.74 | +4.76% |
Oct 30, 2025 | kr34.46 | kr30.66 | -11.03% |
Jul 17, 2025 | kr25.94 | kr27.90 | +7.56% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Hansa Biopharma AB (SE:HNSA) report earnings?
Hansa Biopharma AB (SE:HNSA) is schdueled to report earning on Jul 16, 2026, Before Open (Confirmed).
What is Hansa Biopharma AB (SE:HNSA) earnings time?
Hansa Biopharma AB (SE:HNSA) earnings time is at Jul 16, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Hansa Biopharma AB stock?
The P/E ratio of Hansa Biopharma AB is N/A.
What is SE:HNSA EPS forecast?
SE:HNSA EPS forecast for the fiscal quarter 2026 (Q2) is -1.66.